Effectiveness of psoriatic arthritis therapies

Seminars in Arthritis and Rheumatism

Volumn 33, Issue 1, 2003, Pages 29-37

  Gladman, Dafna D ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Etanercept; Inhibitor; Psoriatic arthritis; Treatment; Tumor necrosis factor

Indexed keywords

ANTIRHEUMATIC AGENT; CHLOROQUINE; CYCLOSPORIN; ETANERCEPT; ETRETINATE; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR RECEPTOR;

ALOPECIA; ANTIINFLAMMATORY ACTIVITY; DERMATITIS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; HUMAN; INFLAMMATORY CELL; JOINT DESTRUCTION; MACROPHAGE ACTIVATION; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RASH; REVIEW; SIDE EFFECT; TREATMENT INDICATION;

EID: 0041826789     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2002.50024     Document Type: Article

References (81)

1. Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, FitzGerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993;36:893-900.
2. Costello PJ, Bresnihan B, O'Farrelly C, FitzGerald O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 1999;26:1117-24.
3. Rahman P, Gladman DD. Preventing disability caused by psoriatic arthritis. Contemp Intern Med 1997;9:27-35.
4. Buskila D, Langevitz P, Gladman DD, Urowitz S, Smythe HA. Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis. J Rheumatol 1992;19:1115-9.
5. Gladman DD. Psoriatic arthritis. Rheum Dis Clin North Am 1998;24:829-44.
6. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PsA) - an analysis of 220 patients. Q J Med 1987;62:127-41.
7. Fournie B, Crognier L, Arnaud C, Zabranieck L, Lascaux-Lefebvre V, Marc V, et al. Proposed classification criteria of psoriatic arthritis: a preliminary study in 260 patients. Rev Rheum Engl Ed 1999;66:446-56.
8. Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986;13:586-92.
9. National Psoriasis Foundation Web site. New research shows I million U.S. adults suffer from psoriatic arthritis. Available at: http://www.psoriasis.org/g300.htm. Accessed February 19, 2002.
10. National Psoriasis Foundation Web site. About psoriasis: psoriatic arthritis. Available at: http://www.psoriasis.org/b300.htm. Accessed November 1, 2001.
11. Boumpas DT, Tassiulas IO. Psoriatic arthritis. In: Primer on the Rheumatic Diseases: An Official Publication of the Arthritis Foundation, Klippel JH, ed. Atlanta, Arthritis Foundation 1998:175-9.
12. Brockbank JE, Schentag C, Rosen C, Gladman DD. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medicine clinical attendees (abstract). Arthritis Rheum 2001;44(suppl 9):S94.
13. Rahman P, Nguyen E, Cheung C, Schentag CT, Gladman DD. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001;28:1041-4.
14. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842-6.
15. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
16. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
17. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Care Res 2001;45:151-8.
18. Mahrle G, Schulze HJ, Braütigam M, Mischer, P, Schopf R, Jung EG, et al. Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study. Br J Dermatol 1996;135:752-7.
19. Liang GC, Barr WG. Leflunomide for psoriasis and psoriatic arthritis (abstr). Arthritis Rheum 1999;42(suppl 9): S323.
20. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two meta-analyses. Arthritis Rheum 1990;33:1449-61.
21. Chang DJ. A survey of drug effectiveness and treatment choices in psoriatic arthritis (abstr). Arthritis Rheum 1999;42(suppl 9):S372.
22. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-9.
23. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford, Update Software 2001;1-18.
24. Espinoza LR, Zakraoui L, Espinoza CG, Gutierrez F, Jara LJ, et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992;19:872-7.
25. Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1990;29:46-9.
26. Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992;19:1724-6.
27. Mader R, Gladman DD, Long J, Gough J, Farewell VT. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med 1995;18:139-43.
28. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995;22:241-5.
29. Marguerie L, Flipo RM, Grardel B, Beaurain D, Duquesnoy B, Delcambre B. Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint Bone Spine 2002;69:275-81.
30. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999;58:220-5.
31. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
32. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
33. Seideman P. Methotrexate - the relationship between dose and clinical effect. Br J Rheumatol 1993;32:751-3.
34. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
35. Black RL, O'Brien WM, Van Scott EJ, Auerbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. JAMA 1964;189:141-5.
36. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
37. Spadaro A, Taccari E, Mohtadi B, Riccieri V, Sensi F, Zoppini A. Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs. Clin Exp Rheumatol 1997;15:609-14.
38. Lacaille D, Stein HB, Raboud J, Klinkhoff AV. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? J Rheumatol 2000;27:1922-7.
39. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-6.
40. Salaffi F, Manganelli P, Carotti M, Subiaco S, Lamanna G, Cervini C. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol 1997;16:296-304.
41. The Australian Multicentre Clinical Trial Group. Sulfasalazine in early rheumatoid arthritis. J Rheumatol 1992;19:1672-7.
42. Hannonen P, Möttönen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993; 36:1501-9.
43. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995;22:894-8.
44. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
45. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998;25:1957-61.
46. Førre O. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 1994;37:1506-12.
47. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med 1991;324:277-84.
48. Rau R, Herborn G, Menninger H, Sangha O. Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol 1998;37:1220-6.
49. Schiff MH, Whelton A. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2000;30:196-208.
50. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A meta-analysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
51. Carette S, Calin A, McCafferty JP, Wallin BA. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arthritis Rheum 1989;32:158-65.
52. Palit J, Hill J, Capell HA, Carey J, Daunt SO, Cawley MI, et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990;29:280-3.
53. Gottlieb S, Hayes E, Gilleaudeau P, Cardinale I, Gottlieb AB, Krueger JG. Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. J Cutan Pathol 1996;23:404-18.
54. Ciompi ML, Bazzichi L, Marotta G, Pasero G. Tigason (etretinate) treatment in psoriatic arthritis. Int J Tissue React 1988;10:25-28.
55. Klinkhoff AV, Gertner E, Chalmers A, Gladman DD, Stewart WD, Schachter GD, et al. Pilot study of etretinate in psoriatic arthritis. J Rheumatol 1989;16:789-91.
56. Clark P, Casas E, Tugwell P, Medina C, Gheno C, Tenorio G, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1993;119:1067-71.
57. Faarvang KL, Egsmose C, Kryger P, Pødenphant J, Ingeman-Nielsen M, Hansen TM. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. Ann Rheum Dis 1993;52: 711-5.
58. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000;43:495-505.
59. Smolen JS. Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis. Scand J Rheumatol 1999;112(suppl):15-21.
60. Liang GC, Barr WG. Long term follow-up of the use of leflunomide (LF) in recalcitrant psoriatic arthritis (PA) and psoriasis (PS) (abstr). Arthritis Rheum 2001;44(suppl 9):S121.
61. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RDR. Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96:146-51.
62. Partsch G, Steiner G, Leeb BF, Dunky A, Bröll H, Smolen JS. Highly increased levels of tumor necrosis factor-a and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997;24:518-23.
63. Partsch G, Wagner E, Leeb BF, Dunky A, Steiner G, Smolen JS. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 1998;25:105-10.
64. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999;26(suppl 57):16-21.
65. Spencer-Green G. Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis 2000;59(suppl I):i46-i49.
66. Enbrel [prescribing information]. Seattle, WA: Immunex Corporation; 2002.
67. Mease P, Kivitz A, Burch F, Siegel E, Cohen S, Burge D. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial (abstr). Arthritis Rheum 2001;44(suppl 9):S90.
68. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
69. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Burge DJ. Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis (abstr). Arthritis Rheum 2000;43(suppl 9):S403.
70. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol 2000;18:732-4.
71. Remicade [prescribing information]. Malvern, Pa: Centocor Inc; 2002.
72. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
73. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 2001;144: 587-9.
74. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
75. Kruithof E, Van Den BF, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one-year follow-up. Ann Rheum Dis 2002;61:207-12.
76. Cauza EE, Spak MS, Cauza KC, Hanusch-Enserer UH, Dunky AD, Wagner EW. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor blocker Infliximab. Rheumatol Int 2002;22:227-32
77. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002;47:506-12.
78. Bray VJ, Huffstutter JE, Schwartzman S. Emerging role of infliximab (Remicade) in psoriatic arthritis patients resistant to disease-modifying antirheumatic drugs: case studies (abstr). Arthritis Rheum 2001;44(suppl 9):S121.
79. Bolce RJ, Thompson J, Stevens MP. Treatment of psoriatic arthritis with infliximab in a small office-based rheumatology practice. Arthritis Rheum 2001;44(suppl 9):S121.
80. Brockbank JE, Lapp V, Gladman DD. Infliximab therapy in 15 patients with psoriatic arthritis (abstr). J Rheumatol 2001;28(suppl. 63):62.
81. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.